Clinical trial

Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer

NCT03982004

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2020-09-14

PhasePHASE1

Study timeline

Study start (actual)2020-09-14Date precision: day

Registry last updated2021-06-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Breast Cancerunresolved

Interventions

Epicutaneous cryoimmunotherapyDEVICE

Topical imiquimodDRUG

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Dermatologic Quality of Life IndexOTHER

Functional Assessment of Cancer TherapyOTHER

Intra-lesional GM-CSFDRUG

Cry-ACDEVICE

Cutaneous tumor biopsyPROCEDURE

Peripheral blood draw for researchPROCEDURE

Sponsors & collaborators

Washington University School of Medicinelead sponsor

Merck Sharp & Dohme LLCcollaborator

Mapped research locations

St LouisMissouri, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03982004 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.